🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

404 results for “treatment” Clear

  1. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  2. Treatment sequence AB

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  3. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  4. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  5. Vancomycin Pre-Treatment

    Seres Therapeutics

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 1 small molecule completed

    1 trial

  6. Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

    Istituto Gentili S.r.l.

    Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.

    phase 1 other active

    1 trial

  7. a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).

    Teva Pharma GmbH

    Pain

    phase 1 small molecule completed

    1 trial

  8. anti-CD123 CAR-T treatment

    Nanjing Legend Biotech Co.

    Acute Leukemia

    phase 1 small molecule terminated

    1 trial

  9. clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontinencee

    The George Institute

    Stress or mixed urinary incontinence in women over 50 years of age not responding to conventional treatments

    phase 1 other active

    1 trial

  10. interceptive orthodontic treatments

    NORTHWEST BIOTHERAPEUTICS INC

    Malocclusion

    phase 1 other active

    1 trial

  11. treatment A

    United Therapeutics Europe Ltd

    Dyslipidemia

    phase 1 small molecule active

    1 trial

  12. „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial

  13. Algorithm Treatment

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    approved small molecule completed

    1 trial

  14. Bismuth-based susceptibility-guided treatment

    Hospital Authority, Hong Kong

    Helicobacter Pylori

    approved small molecule completed

    1 trial

  15. CHLORURE DE SODIUM 0,9 % VIAFLO, solution pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Tour Hekla

    1st line treatment for unresectable metastatic colorectal cancer

    approved small molecule active

    1 trial

  16. Ciprofol

    The First People's Hospital of Lianyungang

    ECMO Treatment

    approved small molecule active

    1 trial

  17. Crysvita (burosumab-twza) Treatment

    Ultragenyx UK Limited

    Epidermal Nevus Syndrome

    approved small molecule completed

    1 trial

  18. DABIGATRAN ETEXILATE , CLOPIDOGREL , RIVAROXABAN , APIXABAN , ACENOCOUMAROL , EDOXABAN

    The George Institute

    patients who are requested a colonoscopy for any indication and are under antiplatelet treatment (except ASA) or anticoagulant treatment

    approved small molecule active

    1 trial

  19. DS-8201a

    AstraZeneca AB

    Treatment of patients with HER2-positive breast cancer with or without brain metastasis

    approved small molecule active

    1 trial

  20. Daratumumab and corticosteroid treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acquired Hemophilia

    approved small molecule active

    1 trial

  21. Diane-35 pretreatment

    The First People's Hospital of Lianyungang

    Polycystic Ovary Syndrome

    approved small molecule active

    1 trial

  22. Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Pierre Fabre Australia Pty Ltd

    giving a commercially available vaccine to women with HIV under treatment, women living with HIV traeted by antiretroviral

    approved small molecule active

    1 trial

  23. HALOPERIDOL, CLOZAPINE, TIAPRIDE, SERTINDOLE, PALIPERIDONE, OLANZAPINE, SULPIRIDE, ARIPIPRAZOLE, LURASIDONE, RISPERIDONE, AMISULPRIDE, CHLORPROMAZINE, PIMOZIDE, QUETIAPINE

    Disc Medicine

    HAMLETT compares regular treatment guidelines for patients in remission after a first episode of psychosis, namely continuation with antipsychotic medication for at least one year, with early dose reduction/discontinuation.

    approved small molecule active

    1 trial

  24. Henagliflozin Proline Tablets treatment

    The First People's Hospital of Lianyungang

    Diabetes Type 2

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources